Sentara Norfolk General Hospital
Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with significant illness and reduced survival. The PHORA-USE Registry (PHORAR) is a prospective, multicenter observational registry designed to collect real-world clinical data from adult and pediatric patients with PAH receiving routine clinical care. The purpose of this registry is to create a centralized database that can be used to better understand patient characteristics, treatment patterns, disease progression, and clinical outcomes. Information collected through the registry will support observational analyses aimed at identifying factors associated with outcomes and may contribute to the development of improved risk assessment and treatment strategies for patients with PAH.
Inclusion Criteria: * Male or female participants, including adults (≥18 years) and pediatric participants (1 day to \<18 years of age). * Diagnosed with pulmonary arterial hypertension (PAH) within the first year of diagnosis or treatment, or treatment-naïve. * Diagnosis of PAH classified as WHO Pulmonary Hypertension Group I (pediatric participants may include Group III), including idiopathic PAH, heritable PAH, and PAH associated with collagen vascular disease, drugs, congenital heart disease, cirrhosis, or HIV. * Right heart catheterization (RHC) demonstrating: * Mean pulmonary arterial p…
Participants receive routine clinical care for pulmonary arterial hypertension as determined by their treating clinicians. No drugs, devices, procedures, diagnostic tests, or clinical interventions are assigned by the study protocol. The only research activity is abstraction of data from existing medical records for inclusion in the registry.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.